NHS Blood and Transplant Clinical Biotechnology Centre implements the Amperia system to streamline viral vector process development for novel gene therapies
The NHSBT Clinical Biotechnology Centre (CBC), Bristol, one of three government selected Innovation Hubs tasked to accelerate the development of novel gene therapies in the UK, has selected the Amperia Redox Electrochemical Detection (RED) system to provide rapid at-line titre data for Adeno-associated viral (AAV) vector process development.
Rapid, accurate quantification of viral titre at every step of the development process is required to check viral particle recovery and quality. Real-time process optimisation was impacted by delays in access to AAV titre data due to a requirement to batch samples for analysis.
The Amperia system provides a rapid automated platform for AAV titre analysis with flexible throughput. Titre can be measured cost-effectively at-line without the need to batch, store or transfer samples. Yields from unit operations in the viral manufacturing process can be assessed immediately and process adjustments made to avoid wastage of expensive consumables and time.
“Speed, accuracy and flexibility are important for us when looking for an AAV quantification solution, along with cost. Our clients rely on us to meet their process development targets, and having access to accurate titre data in near real-time throughout process optimisation will allow us to maximise efficiency and provide client updates quickly and confidently,” said Laura Barry, Development Scientist, NHSBT CBC. “The Amperia system is very user friendly and compact, with no additional computer equipment to accommodate in the busy lab.”
“We are delighted to be able to support the CBC team to streamline their process development workflows by providing simple agile access to AAV titre data for immediate process adjustments.” commented Ruizhi Wang, Abselion CEO.
To learn more read the full case study: here
Ruby Satti, Analytical Scientist, NHSBT-CBC with the Amperia system.
For media enquiries, please contact: info@abselion.com
About Abselion
Abselion is a Cambridge, UK-based innovator in automated analytical instrumentation simplifying at-line protein analytics for the development and production of biologics, such as antibodies and viral vectors. Pioneering the highly sensitive and specific, Redox-Electrochemical-Detection (RED) technology, Abselion seeks to streamline and accelerate access to process insights in biopharmaceutical research, development and production. Abselion combines the expertise of an interdisciplinary team working at the intersection of biology, nanotechnology and engineering. Learn more at www.abselion.com or follow us on LinkedIn @abselion.
About NHSBT Clinical Biotechnology Centre (CBC)
The Clinical Biotechnology Centre (CBC), Bristol, was opened in April 1999. Our aim is to be the preferred provider of quality-assured DNA and protein-based therapeutics for healthcare, academic and commercial customers seeking to establish the safety and efficacy of innovative cellular and molecular therapies. Learn more at www.nhsbt.nhs.uk/cellular-and-molecular-therapies/clinical-biotechnology-centre
About Innovation Hubs for Gene Therapies
The network of Innovation Hubs for Gene Therapies aims to accelerate academic-led development of novel gene therapies throughout the UK. Set up in 2021 with £18m in funding from the independent research charity LifeArc, the Medical Research Council (MRC), and the Biotechnology and Biological Sciences Research Council (BBSRC), the hubs operate as a coordinated network, sharing technical skills and resources. Three new dedicated facilities have been created at King’s College London, NHS Blood and Transplant in Bristol, and the University of Sheffield. The hubs enable academic researchers to progress novel gene therapy research into clinical trials, offering access to good manufacturing practice (GMP) facilities for clinical trials materials, alongside essential translational support and regulatory advice. Learn more at www.genetherapyhubs.uk